Results 121 to 130 of about 32,079 (282)

An infectious recombinant foot-and-mouth disease virus expressing a fluorescent marker protein

open access: green, 2013
Julian Seago   +6 more
openalex   +2 more sources

Foot-and-Mouth Disease Virus [PDF]

open access: yes, 2019
Francisco Sobrino   +3 more
openaire   +1 more source

Clinical, Neuroimaging and Video Electroencephalography Findings in Children With Congenital Zika Syndrome: An Analysis From a Neurorehabilitation Centre

open access: yesInternational Journal of Developmental Neuroscience, Volume 86, Issue 2, April 2026.
Children with congenital Zika syndrome followed at a neurorehabilitation centre demonstrated severe neurological impairment characterized by microcephaly, cortical malformations, intracranial calcifications and multifocal epileptiform activity. Integrated clinical, neuroimaging and video‐electroencephalographic (EEG) findings highlight the extensive ...
Adilina Soares Romeiro Rodrigues   +5 more
wiley   +1 more source

A novel immunoinformatic approach for design and evaluation of heptavalent multiepitope foot-and-mouth disease virus vaccine [PDF]

open access: gold
Mostafa R. Zaher   +5 more
openalex   +1 more source

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

open access: yesMedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Foot-and-Mouth Disease Vaccines by Design; Production of Capsid-Modified Foot-and-Mouth Disease Viruses with Improved Cell Culture Growth [PDF]

open access: gold
Stephen Berryman   +5 more
openalex   +1 more source

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 955-966, April 2026.
In the phase I/IIa GOING trial, an add‐on strategy with regorafenib followed by nivolumab showed a manageable safety profile and meaningful clinical activity in second‐line hepatocellular carcinoma, with a median overall survival of 25 months and 45% three‐year survival in sorafenib‐experienced patients.
Marco Sanduzzi‐Zamparelli   +24 more
wiley   +1 more source

Cryptococcid Sweet Syndrome in the Setting of Hydralazine‐Induced ANCA Vasculitis: A Case Report

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 4, Page 356-361, April 2026.
ABSTRACT Acute febrile neutrophilic dermatosis, also known as Sweet syndrome, is an inflammatory skin condition characterized by the rapid onset of painful, erythematous plaques or nodules with neutrophilic infiltrate on histology. Rarely, acellular bodies surrounded by vacuolated spaces have been noted within the neutrophilic infiltrate, mimicking ...
Jenna Vroman   +4 more
wiley   +1 more source

‘What Do People With Long Covid Want From Healthcare Services?’ A Qualitative Exploration From Lived Experience

open access: yesHealth Expectations, Volume 29, Issue 2, April 2026.
ABSTRACT Background Long COVID (LC) is a chronic, multisystem condition affecting millions globally, with significant personal, social and economic consequences. Despite increasing recognition of its impact, healthcare services for LC remain inconsistent with patients frequently encountering fragmented services, scepticism and delays leading to patient‐
Clare Rayner   +67 more
wiley   +1 more source

Home - About - Disclaimer - Privacy